Treatment of lupus nephritis

Seminars in Nephrology

Volumn 16, Issue 6, 1996, Pages 527-535

  Austin, Howard A ^a,b   Boumpas, Dimitrios T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; GLUCOCORTICOID; GRANISETRON; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; MESNA; METHYLPREDNISOLONE; ONDANSETRON; PREDNISONE;

AMENORRHEA; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SAFETY; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE COMPLEX DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPH NODE IRRADIATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL;

ANIMALS; CLINICAL TRIALS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; LUPUS NEPHRITIS; PROGNOSIS;

EID: 0029964922     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Churg J, Sobin LH: Renal Disease: Classification and Atlas of Glomerular Disease Tokyo, Igaku-Shoin, 1982, pp 127-149
2. Couser WG: Pathogenesis of glomerulonephritis Kidney Int 44:19-26, 1993 (suppl 42)
3. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease N Engl J Med 318:1657-1666, 1988
4. Keane WF, Kasiske BL, O'Donnell MP, et al: Hypertension, hyperlipidemia, and renal damage Am J Kidney Dis 21:43-50, 1993 (suppl 2)
5. Wofsy D, Seaman WE: Successful treatment of autoimmunity in NZB/NZW Fl mice with monoclonal antibody to L3T4 J Exp Med 161:378-391, 1985
6. Shlomchik MJ, Madaio MP, Ni D, et al: The role of B cells in lpr/lpr-induced autoimmunity J Exp Med 180:1295-1306, 1994
7. Madaio MP, Shlomchik MJ: Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis B cells have multiple roles; all autoantibodies are not equal J Am Soc Nephrol 7:387-396, 1996
8. Hahn BH, Tsao BP: Antibodies to DNA, in Wallace DJ, Hahn BH (eds): Dubois' Lupus Erythematosus, 4th ed Philadelphia, PA, Lea & Febiger, 1993, pp 195-201
9. Foster MH, Cizman B, Madaio MP: Nephritogenic autoantibodies in systemic lupus erythematosus: Immunochemical properties, mechanisms of immune deposition, and genetic origins Lab Invest 69:494-507, 1993
10. Fries JVVU, Mendrick DL, Hennke HG: Determinants of immune complex-mediated glomerulonephritis Kidney Int 34:333-345, 1988
11. Weiss SJ: Tissue destruction by neutrophils N Engl J Med 320:365-376, 1989
12. Johnson RJ, Alpers CE, Pritzl P, et al: Platelets mediate neutrophil-dependent immune complex nephritis in the rat J Clin Invest 82:1225-1235, 1988
13. Schreiner OF: The role of the macrophage in glomerular injury Semin Nephrol 11:268-275, 1991
14. Termaat RM, Assmann KJ, Dijkman HB, et al: Anti-DNA anibodies can bind to the glomerulus via two distinct mechanisms Kidney Int 42:1363-1371, 1992
15. Kerjaschki D: The pathogenesis of membranous glomerulonephritis: From morphology to molecules Virchows Archiv B Cell Pathol IncI Mol Pathol 58:253-271, 1990
16. Floege J, Kriz W, Schulze M, et al: Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy J Clin Invest 96:2809-2819, 1995
17. Knauss TC, Mene P, Ricanati SA, et al: Immune complex activation of rat glomerular mesangial cells: Dependence on the Fc region of antibody Am J Physiol 257:F478-F485, 1989
18. Floege J, Eng E, Young BA, et al: Factors involved in the regulation of glomerular mesangial cell proliferation in vitro and in vivo Kidney Int 43:47-54, 1993 (suppl 39)
19. Johnson RJ: The glomerular response to injury: Progression or resolution Kidney Int 45:1769-1782, 1994
20. Floege J, Eng E, Young B A, et al: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats J Clin Invest 92:2952-2962, 1993
21. Frampton G, Hildreth G, Hartley B, et al: Could platelet-derived growth factor have a role in the pathogenesis of lupus nephritis? Lancet 2:343, 1988
22. Isaka Y, Fujiwara Y, Ueda N, et al: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney J Clin Invest 92:2597-2601, 1993
23. Border \VA, Noble B, Yamamoto T, et al: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease Nature 360:361-364, 1992
24. Hebert LA, Dillon JJ, Middendorf DF, et al: Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus Am J Kidney Dis 26:432-438, 1995
25. Ginsberg JM, Chang BS, Matarese RA, et ai: Use of single voided urine samples to estimate quantitative proteinuria N Engl J Med 309:1543-1546, 1983
26. Schwab SJ, Christensen L, Dougherty K, et al: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples Arch Intern Med 147:943-944, 1987
27. Shemesh O, Golbetz H, Kriss JP, et al: Limitations of creatinine as a filtration marker in glomerulopathic patients Kidney Int 28:830-838, 1985
28. Zaltzman JS, Whiteside C, Cattran DC, et al: Accurate measurement of impaired glomerular filtration using single-dose oral cimetidine Am J Kidney Dis 27:504-511, 1996
29. Hill OS, Hinglais N, Tron F, et al: Systemic lupus erythematosus: Morphologic correlations with immunologie and clinical data at the time of biopsy Am J Med 64:61-79, 1978
30. Pillemer SR, Austin HA, Tsokos GC, et al: Lupus nephritis: association between serology and renal biopsy measures J Rheumatol 15:284-288, 1988
31. ter Borg EJ, Horst G, Hummel EJ, et al: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus A long-term, prospective study Arthritis Rheum 33:634-643, 1990
32. Swaak AJG, Groenwold J, Bronsveld W: Predictive value of complement profiles and anti-ds DNA in systemic lupus erythematosus Ann Rheum Dis 45:359-366, 1986
33. Chan TM, Cheng IKP: A prospective study on antiendothelial cell antibodies in patients with systemic lupus erythematosus Clin Immunol Immunopathol 78:41-46, 1996
34. Siegert CEH, Daha MR, Tseng CMES, et al: Predictive value of IgG autoantibodies against Clq for nephritis in systemic lupus erythematosus Ann Rheum Dis 52:851-856, 1993
35. Bootsma H, Spronk P, Derksen R, et al: Prevention of relapses in systemic lupus erythematosus Lancet 345:1595-1599, 1995
36. Walz LeBIanc BAE, Gladman DD, Urowitz MB: Serologically active clinically quiescent systemic lupus erythematosis-Predictors of clinical flares J Rheumatol 21:2239-2241, 1994
37. Esdaile JM, Joseph L, Mackenzie T, et al: The benefit of early treatment with immunosuppressive agents in lupus nephritis J Rheumatol 21:2046-2051, 1994
38. Magil AB, Puterman ML, Ballon HS, et al: Prognostic factors in diffuse proliferative lupus glomerulonephritis Kidney Int 34:511-517, 1988
39. Nossent HC, Henzen-Logmans SC, Vroom TM, et al: Contribution of renal biopsy data in predicting outcome in lupus nephritis Analysis of 116 patients Arthritis Rheum 33:970-977, 1990
40. Esdaile JM, Federgreen W, Quintal H, et al: Predictors of one year outcome in lupus nephritis: The importance of renal biopsy Q J Med 81:907-918, 1991
41. McLaughlin JR, Bombardier C, Farewell VT, et al: Kidney biopsy in systemic lupus erythematosus III Survival analysis controlling for clinical and laboratory variables Arthritis Rheum 37:559-567, 1994
42. Austin HA, Boumpas DT, Vaughan EM, et al: Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologie data Kidney Int 45:544-550, 1994
43. Austin HA, Boumpas DT, Vaughan EM, et al: High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients Nephrol Dial Transplant 10:1620-1628, 1995
44. Ginzler EM, Diamond HS, Weiner M, et al: A multicenter study of outcome in systemic erythematosus I Entry variables as predictors of prognosis Arthritis Rheum 25:601-611, 1982
45. Levey AS, Lan S-P, Corwin HL, et al: Progression and remission of renal disease in the Lupus Nephritis Collaborative Study Results of treatment with prednisone and short-term oral cyclophosphamide Ann Intern Med 116:114-123, 1992
46. Reveille JD, Bartolucci A, Alarcon GS: Prognosis in systemic lupus erythematosus Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death Arthritis Rheum 33:37-48, 1990
47. Ginzler EM, Felson DT, Anthony JM, et al: Hypertension increases the risk of renal deterioration in systemic lupus erythematosus J Rheumatol 20:1694-1700, 1993
48. Appel GB, Suva FG, Pirani CL, et al: Renal involvement in systemic lupus erythematosus (SLE): A study of 56 patients emphasizing histologie classification Medicine 57:371-410, 1978
49. Bakir AA, Levy PS, Dunea G: The prognosis of lupus nephritis in African-Americans: A retrospective analysis Am J Kidney Dis 24:159-171, 1994
50. Salmon JE, Millard S, Shachter LA, et al: FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans J Clin Invest 97:1348-1354, 1996
51. Ward MM, Pyun E, Studenski S: Long-term survival in systemic lupus erythematosus Patient characteristics associated with poorer outcomes Arthritis Rheum 38:274-283, 1995
52. Esdaile JM, Levinton C, Federgreen W, et al: The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature Q J Med 72:779-833, 1989
53. Kimberly RP, Lockshin MD, Sherman RL, et al: "End-stage" lupus nephritis: Clinical course to and outcome on dialysis Medicine 60:277-287, 1981
54. Whiting-O'Keefe Q, Henke JE, Shearn MA, et al: The information content from renal biopsy in systemic lupus erythematosus: Step-wise linear regression analysis Ann Intern Med 96:718-723, 1982
55. Donadio JV, HoIIey KE, Ferguson RH, et al: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide N Engl J Med 299:1151-1155, 1978
56. Dinant HJ, Decker JL, Klippel JH, et al: Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis Ann Intern Med 96:728-736, 1982
57. Balow JE, Austin HA, Muenz LR, et al: Effect of treatment on the evolution of renal abnormalities in lupus nephritis N Engl J Med 311:491-495, 1984
58. Austin HA, Klippel JH, Balow JE, et al: Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs N Engl J Med 314:614-9, 1986
59. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone onlyArthritis Rheum 34:945-950, 1991
60. McCune VJ, Golbus J, Zeldes W, et al: Clinical and immunologie effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus N Engl J Med 318:1423-1431, 1988
61. Zhu L-P, Cupps TR, Whalen G, et al: Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells J Clin Invest 79:1082-1090, 1987
62. Austin HA, Patel AD, Balow JE: Immunologic effects of short courses of pulse cyclophosphamide in a murine model of SLE J Am Soc Nephrol 6:918, 1995 (abstr)
63. Fox DA, McCune WJ: Immunologie and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus, in Cruse JM, Lewis RE, Jr (eds): Therapy of Autoimmune Diseases, Concepts in Immunopathology Basel, Karger, 1989, pp 20-79
64. Chan T-M, Li F-K, Wong RWS, et al: Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone Nephron 71:321-327, 1995
65. Lehman TJ, Sherry DD, Wagner-Weiner L, et al: Intermittent intravenous cyclophosphamide therapy for lupus nephritis J Pediatr 114:1055-1060, 1989
66. Boumpas DT, Austin HA, Vaughan EM, et al: Controlled trial of pulse methylprednisone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 340:741-745, 1992
67. Boumpas DT, Austin HA, Vaughan EM, et al: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy Ann Intern Med 119:366-369, 1993
68. Hellmann DB, Petri M, Whiting-O'Keefe Q: Fatal infections in systemic lupus erythematosus: The role of opportunistic organisms Medicine 66:341-348, 1987
69. Gibbons RB, Westerman E: Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis Arthritis Rheum 31:1552-54, 1988
70. Vasquez S, Kavanaugh AF, Schneider NR, et al: Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents J Rheumatol 19:1625-1627, 1992
71. Fraenkel L, Mackenzie T, Joseph L, et al: Response to treatment as a predictor of longterm outcome in patients with lupus nephritis J Rheumatol 21:2052-2057, 1994
72. Gourley M, Austin HA, Yarboro C, et al: Randomized trial of multiple boluses of methylprednisolone (MP) or cyclophosphamide (CY) or the combination (CY/MP) in patients with lupus nephritis (abstract) Arthritis Rheum 38:392, 1995 (suppl 9)
73. Cheigh JS, Stenzel KH: End-stage renal disease in systemic lupus erythematosus Am J Kidney Dis 21:2-8, 1993
74. Strober S, Farinas MC, Field EH, et al: Treatment of lupus nephritis with total lymphoid irradiation Arthritis Rheum 31:850-858, 1988
75. Favre H, Miescher PA, Huang YP, et al: Cyclosporin in the treatment of lupus nephritis Am J Nephrol 9:57-60, 1989 (suppl 1)
76. Lewis EJ, Hunsicker LG, Lan SP, et al: A controlled trial of plasmapheresis therapy in severe lupus nephritis The Lupus Nephritis Collaborative Study Group N EngI J Med 326:1373-1379, 1992
77. Euler HH, Schroeder JO, Harten P, et al: Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide Arthritis Rheum 37:1784-1794, 1994
78. Sloan RP, Schwartz MM, Korbet SM, et al: Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis J Am Soc Nephrol 7:299-305, 1996
79. Ordonez JD, Hiatt RA, Killebrew EJ, et al: The increased risk of coronary heart disease associated with nephrotic syndrome Kidney Int 44:638-642, 1993
80. Austin HA, Antonovych TT, MacKay K, et al: Membranous nephropathy Ann Intern Med 116:672-682, 1992
81. Radhakrishnan J, Kunis CL, D'Agati V, et al: Cyclosporine treatment of lupus membranous nephropathy Clin Nephrol 42:147-154, 1994
82. Vlahakos D, Foster MH, Ucci AA, et al: Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo J Am Soc Nephrol 2:1345-1354, 1992
83. Houssiau FA, D'Cruz DP, Haga H-J, et al: Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: A preliminary study Lupus 1:31-35, 1991
84. Dawisha SM, Yarboro CH, Vaughan EM, et al: Outpatient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosus J Rheumatol 23:273-278, 1996
85. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease The Modification of Diet in Renal Disease Study Ann Intern Med 123:754-762, 1995
86. 86The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus N Engl J Med 324:150-154, 1991
87. Clark WF, Parbtani A, Huff MW, et al: Flaxseed: A potential treatment for lupus nephritis Kidney Int 48:475-480, 1995